Merck & Co’s Keytruda Gets Foot In The Door For First-Line Gastric Cancer
Results presented as ASCO from the mixed KEYNOTE-062 study suggest a place for pembrolizumab in first-line gastric cancer but data from other ongoing trials will be needed to support filings amid looming competition from Opdivo.
You may also be interested in...
A new frontier for IO therapies in gastric/gastroesophageal cancers is opening up on positive data for two leading checkpoint inhibitors in first-line advanced disease where BMS’s Opdivo looks likely to have an advantage over Merck & Co’s Keytruda.
Merck's KEYNOTE-061 gastric cancer study is the latest example of a checkpoint inhibitor failing in Phase III after accelerated approval.
Disappointing outcome for the companies' PD-L1 inhibitor avelumab in late-stage gastric cancer may not have implications for the drug in more valuable indications, like lung cancer.